medigraphic.com
Academia Mexicana de Neurología, A.C.

2015, Number 2

<< Back

Rev Mex Neuroci 2015; 16 (2)

Utility of the memantine in late cognitive deterioration secondary to radiotherapy: Case report and literature review

Schiappacasse-Cocio G, González-Soto P

Language: Spanish
References: 14
Page: 62-69
PDF size: 206.91 Kb.


ABSTRACT

Introduction: Late CNS complications secondary to radiotherapy are more frequently seen, affecting significantly the patients’ quality of life. There is no approved pharmacological treatment for this type of late cognitive decline.
Case report: We evaluated clinically a patient with late cognitive decline attributed to radiotherapy. A trial with memantine showed benefits on his cognitive performance. A statistical analysis was in use type goodness of fit with statistics chi square, to evaluate the impact of the medicament in this case with cognitive late dysfunction. There was obtained a beneficial not attributable result at random.
Conclusions: Memantine could be useful in the treatment of late cognitive decline due to radiotherapy. However, it is necessary information derived from clinical trials to conclude that memantine is effective in tardive dementia associated with radiotherapy.


REFERENCES

  1. Cross NE, Glantz MJ. Neurologic complications of radiation therapy. Neurol Clin N AM 2003; 21: 249-277.

  2. Chi D, Béhin A, Delattre JY. Neurologic complications of radiation therapy. In: Schiff D, Kesari S, Wen PY, eds. Cancer neurology in clinical practice. Neurologic complications of cancer and its treatment, 2008: 259-286.

  3. De Angelis LM, Posner JB. Side Effects of radiation therapy. In: De Angelis LM, Posner JB, eds. Neurologic complications of cancer, 2009: 511-55.

  4. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroproteccion. Mol Interv 2004; 4: 273-284.

  5. Kim JH, Brown SL, Jenrow KA, Ryu S. Mechanisms of radiation-induced brain toxicity and implications for future clinical trials. J Neurooncol 2008; 87: 279-286.

  6. Soussain C, Ricard C, Fike JR, Mazeron JJ, Psimaras D, Delattre Y. CNS complication of radiotherapy and chemotherapy. Lancet 2009; 374: 1639-1651.

  7. Meyers C, Wefel J.The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifi, ands, buts, or sensitivity. Journal of Clinic Oncology 2003; 21: 3557-3558.

  8. Quiroga P, Albala C, Klaasen G. Validation of a screening test for age associated cognitive impairment in Chile. Rev. méd. Chile 2004; 132: 467-478.

  9. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensiveassesment of psychopatology in dementia. Neurol 1994; 44: 2308-2314.

  10. Vilalta J, Lozano M, Hernández M, Llinás J, López S, López L. Neuropsychiatric Inventory: propiedades psicométricas de su adaptación al español. Neurol 1999; 29: 9-15.

  11. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003; 9: 180-188.

  12. Yang I, Huh NG, Smith ZA, Han SJ, Parsa AT. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin N Am 2010; 21: 181-186.

  13. Brown PD, Shook S, Laack NN, Wefel JS, Choucair A, Suh JH, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiation therapy (WBRT): first report of RTOG 0614, a placebo-controlled, double-blind, randomized trial. Int J radiat 2012; 84: 1-3.

  14. Orgorozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of Memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial. Stroke 2002; 33: 1834-1839.




2020     |     www.medigraphic.com